SecBot SecBot
EFFECT ·Filed Apr 21, 2026

ANRO

Alto Neuroscience, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC9999999995-26-001257
IPO/offering going effective
Actionable Insight • Neutral

Monitor for 144 filings or prospectus supplements indicating actual sales under this shelf, which could pressure the stock price due to incremental supply. The overhang from potential sales may weigh on near-term sentiment despite no immediate dilution.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
ANRO ▲ +6.80% at T+60d
NEUTRAL call +6.80% · α vs SPY -0.10% · entry $25.59 → $27.33
Entry = T+0 close
Apr 21, 2026
via day close
T+1d
+6.14%
call +6.14% · α +5.12%
$27.16
settled 6mo ago
T+5d
-4.38%
call -4.38% · α -5.46%
$24.47
settled 6mo ago
T+20d
-14.81%
call -14.81% · α -19.73%
$21.80
settled 5mo ago
T+60d
+6.80%
call +6.80% · α -0.10%
$27.33
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Alto Neuroscience's shelf registration (Form S-3) has become effective, allowing selling stockholders to offer up to 8,454,514 shares, including shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from the resale, except nominal amounts if warrants are exercised for cash.

Key Facts

  • Shelf registration Form S-3 (File No. 333-294974) became effective on April 20, 2026.
  • Up to 8,454,514 shares may be sold by selling stockholders, consisting of 3,832,263 existing shares and 4,622,251 shares underlying pre-funded warrants.
  • The shares were acquired in a private placement on October 21, 2025.
  • The company will not receive proceeds from the resale of shares, only nominal proceeds if pre-funded warrants are exercised at $0.0001 per share.

Financial Impact

Up to 8,454,514 shares may be sold over time, representing potential dilution; no proceeds to the company.

dilutionshare_count

Risk Factors

  • Potential share price pressure if selling stockholders offload large volumes quickly.
  • Increased share float could lead to higher volatility.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001257
Document: 9999999995-26-001257-index.html9999999995-26-001257
Document: 9999999995-26-001257.txt9999999995-26-001257
12 reports for ANRO
Performance horizon
83% Hit rate @ T+5 5 of 6 directional calls Went positive at some point 6 of 6 best @ T+60▲ +66.79%Jun 11, 2026
Filters
Rows
Reports for ANRO — sortable, filterable
TypeNow
Aug 12, 2026
10w ago
Institutional Cluster
BULLISH ★ 6/10
$32.30 $34.25▲ +6.04%▲ +8.00%$23.19 (−28.20%)
Jul 14, 2026
15w ago
8-K
BEARISH ★ 6/10
$27.80 $25.90▲ +6.83%▲ +5.54%$23.19 (+16.58%)
Jul 14, 2026
15w ago
424B5
BEARISH ★ 6/10
$27.80 $25.90▲ +6.83%▲ +5.54%$23.19 (+16.58%)
Jul 13, 2026
15w ago
8-K
BULLISH ★ 6/10
$28.03 $27.54▼ −1.75%▼ −0.96%$23.19 (−17.27%)
Jun 11, 2026
19w ago
Institutional Cluster
BULLISH ★ 7/10
$21.47 $22.74▲ +5.92%▲ +5.24%$23.19 (+8.01%)
May 29, 2026
21w ago
3
NEUTRAL ★ 2/10
$19.80 $18.26▼ −7.78%▼ −5.03%$23.19 (+17.12%)
May 28, 2026
21w ago
8-K
NEUTRAL ★ 3/10
$20.22 $18.85▼ −6.78%▼ −6.73%$23.19 (+14.69%)
May 13, 2026
23w ago
8-K
MIXED ★ 6/10
$22.85 $20.45▼ −10.50%▼ −9.35%$23.19 (+1.49%)
Apr 21, 2026
27w ago
EFFECT
NEUTRAL ★ 3/10
$25.59 $24.47▼ −4.38%▼ −5.46%$23.19 (−9.38%)
Apr 10, 2026
28w ago
S-3
NEUTRAL ★ 3/10
$25.75 $27.33▲ +6.14%▲ +2.84%$23.19 (−9.94%)
Showing 10 of 12

US Market Status

Market Closed — Opens Thu (11h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026